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Summary
Background: Follow- up data on patients with 46,XY partial gonadal dysgenesis 
(PGD) until adulthood are scarce, making information on prognosis difficult.
Objective: To analyse the long- term outcomes of patients with 46,XY PGD regarding 
testosterone production, germ cell tumour risk, genotype and psychosexual adaptation.
Methods: A retrospective longitudinal study of 33 patients (20 assigned male and 
13 patients assigned female at birth). Molecular diagnosis was performed by Sanger 
sequencing or by targeted massively parallel sequencing of 63 genes related to dis-
orders of sex development (DSDs).
Results: Age at first and last visit ranged from 0.1 to 43 and from 17 to 53 years, 
 respectively. Spontaneous puberty was observed in 57% of the patients. During 
 follow- up, six of them had a gonadectomy (four due to female gender, and two  because 
of a gonadal tumour). At last evaluation, five of six patients had adult male testosterone 
levels (median 16.7 nmol/L, range 15.3- 21.7 nmol/L) and elevated LH and FSH levels. 
Germ cell tumours were found in two postpubertal patients (one with an abdominal 
gonad and one patient with Frasier syndrome). Molecular diagnosis was possible in 11 
patients (33%). NR5A1 variants were the most prevalent molecular defects (n = 6), and 
four of five patients harbouring them developed spontaneous puberty. Gender change 
was observed in four patients, two from each sex assignment group; all patients reported 
satisfaction with their gender at final evaluation. Sexual intercourse was reported by 
81% of both gender and 82% of them reported satisfaction with their sexual lives.
Conclusion: Spontaneous puberty was observed in 57% of the patients with 46,XY 
PGD, being NR5A1 defects the most prevalent ones among all the patients and in 
those with spontaneous puberty. Gender change due to gender dysphoria was 
 reported by 12% of the patients. All the patients reported satisfaction with their final 
gender, and most of them with their sexual life.
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1  | INTRODUC TION
The 46,XY disorder of sex development (DSD) due to gonadal dys-
genesis is a congenital disorder caused by alterations in the complex 
process of gonadal determination.1 There is a wide phenotype spec-
trum ranging from a partial form, characterised by variable degrees 
of external genitalia undervirilisation, development of Mullerian 
derivatives and testosterone production, to a complete form with 
female external and internal genitalia.
There are scarce data on long- term follow- up of 46,XY partial 
gonadal dysgenesis (PGD) patients, regarding spontaneous puberty,2 
risk of a gonadal tumour development3 and gender adjustment, mak-
ing it difficult to provide comprehensive information to parents.
Our aim was to describe the phenotype, genotype and long- term 
outcomes of a large cohort of patients with 46,XY PGD followed 
until adulthood.
2  | SUBJEC TS AND METHODS
Thirty- three patients with 46,XY PGD were included in this retro-
spective longitudinal study conducted at Hospital das Clínicas of 
São Paulo (HCFMUSP). Twenty- six patients were initially evaluated 
at our service, and 7 had already had a previous genitoplasty and/
or gonadectomy elsewhere. Written informed consent was obtained 
from all the patients. The clinical and molecular data from 8 patients 
were previously reported.4-7
Inclusion criteria were as follows: ≥17 years of age at last eval-
uation, a 46,XY karyotype in a G- banded karyotyping analysis of at 
least 30 peripheral blood lymphocytes, atypical genitalia associated 
with the presence of Mullerian derivatives and/or at least one gonad 
with histopathological features compatible with testicular dysgene-
sis. Data regarding sex assignment, age at first and last evaluation, 
external genitalia appearance, the hormonal profile throughout the 
follow- up and at last visit, pubertal development and gonadal tu-
mour incidence were collected from medical records. Patients were 
assumed to be at prepubertal age if they were younger than 9 years, 
at pubertal age if they were 9.1- 16 years old, and at adult age if they 
were older than 17 years. Micropenis is defined as a normally struc-
tured penis which in its fully stretched length is 2.5 standard devia-
tions (SDs) below the mean for age8 and microphallus is defined as a 
micropenis associated with hypospadias.
The external masculinisation score (EMS) was calculated as pre-
viously described.9 To determine the hormonal profile, luteinising 
hormone (LH), follicle- stimulating hormone (FSH) and testosterone 
were measured by immunoradiometric or immunofluorimetric assays 
at the first and at each semi- annual follow- up visit. Spontaneous pu-
berty was assumed if virilisation was observed in pubertal patients 
or was reported by the patients that came in adulthood in conjunc-
tion with the presence of pubertal signs (the presence of secondary 
sex characteristics, such as increased penile length and testis diame-
ter > 2.5 cm, when they were palpable) and with male serum testos-
terone levels without the use of exogenous testosterone.
For prepubertal patients, a human chorionic gonadotropin (hCG) 
test was performed by means of 4 intramuscular injections at 50- 
100 IU/kg each, with a 4- day interval between the injections. A 
single dose of 5000 IU of hCG was administered to adult patients. 
Serum levels of testosterone were measured before and 72 hours 
after the last hCG injection.
Data on a gonadal histology were collected from medical 
records.
Physical evaluation of the palpable scrotal testes of male patients 
was performed at every medical visit (each semester or annually), 
and testicular ultrasonography was performed once every 2 years. 
If a suspicious nodule was identified, tumour markers (β- HCG, α- 
fetoprotein and carcinoma embryonic antigen) were tested, and a 
gonadectomy was indicated if needed.
Continuous variables were described as median and range. 
Differences in the categorical variables among the groups were ana-
lysed by the Chi- square test or Fisher’s exact test, when appropriate. 
The Mann- Whitney U test served as a nonparametric test, and data 
with P < .05 were considered statistically significant. All analyses 
were performed in SPSS Statistics 24.0 software (Chicago, IL).
Evaluation of psychosexual characteristics was performed on 21 
patients by a psychologist specializing in DSDs. Self- reported gen-
der identity, the self- reported gender role in childhood, the desire to 
change gender and satisfaction with gender and with their sexual life 
were analysed via a questionnaire (see Appendix 1).
For molecular diagnosis, genomic DNA was obtained from pe-
ripheral blood leucocytes by the proteinase K–SDS salting- out 
method.10 Six genes involved in testicular dysgenesis (SRY, NR5A1, 
CBX2, MAPK3, FGF9 and FGFR2) were previously sequenced by the 
Sanger method in patients 1, 3, 10, 14, 26 and 30. Patients 15 and 
31 had only WT1 variants screened, considering their phenotypic 
features, as previously reported in great detail.5,6 The entire coding 
region and the exon- intron boundary areas of each gene were PCR- 
amplified with specific primers. The PCR products were sequenced 
according to the protocol of the ABI Prism BigDye Terminator Cycle 
Sequencing Ready Reaction Kit (Life Technologies Corporation, CA, 
USA) on an ABI Prism Genetic Analyzer 3130XL (Life Technologies 
Corporation, CA, USA).
Twenty- seven patients were analysed during the 2010s by tar-
geted massively parallel sequencing. An amplicon- based capture 
panel was designed against exonic regions of 63 genes, including 
43 genes already associated with human DSDs and 20 candidate 
genes involved in gonadal determination pathways or with a DSD 
phenotype in rats1,11-18 (see Appendix 2). Capture of the target 
sequences was performed using a custom Sure Select Target 
Enrichment System Kit (Agilent). Sequencing was performed on 
the Illumina MiSeq platform. Paired- end reads (2 × 300) were 
aligned to the hg19 assembly of the human genome with BWA- 
MEM.19 The aligned reads were sorted and converted to the 
BAM format using the bamsort tool from the biobambam2 suite 
(https://launchpad.net/biobambam2). Mean coverage was over 
95× for all the samples, and more than 96% of the RefSeq gene 
coding regions was covered at 20× or greater. Single- nucleotide 
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variants and small insertions or deletions (indels) were simulta-
neously called in all samples in the Freebayes software (https://
github.com/ekg/freebayes). Annotation of the variants was per-
formed in ANNOVAR.20 For prioritizing the most likely patho-
genic variants, we filtered out those with a minor allele frequency 
>0.5% in available population databases Genome Aggregation 
Database (gnomAD),21 1000 Genomes,22 and in the Brazilian 
population database ABraOM.23 To assess the possible impact of 
the novel nonsynonymous variants on protein structure and func-
tion, we employed in silico algorithms (SIFT, PolyPhen2, Mutation 
Assessor, and CADD) and conservation scores (GERP++, PhyloP). 
These variants were considered deleterious when predicted as 
pathogenic by at least three algorithms. The variants were classi-
fied according to the American College of Medical Genetics and 
Genomics guidelines (ACMG).24
3  | RESULTS
The patients’ age at first visit ranged from 10 days to 43 years (median 
13 years), and at last visit, from 17 to 53 years (median 26.5 years). 
Follow- up ranged from 3 to 26 years (median 13.2 years). Nineteen 
patients had Mullerian derivatives (57%). Histological analysis iden-
tified testicular dysgenesis in 18 patients (67%) and the absence of 
gonadal tissue in 9 (33%).
3.1 | Sex assignment and the EMS
Thirteen patients were assigned female and 20 were assigned male 
at birth. Twenty- six patients were assigned before the year 1990 
(16 patients to male and 10 patients to female), and seven patients 
were assigned between 1990 and 1999 (4 patients to male and 3 
patients to female). The median EMS at first evaluation in patients 
without a previous genitoplasty was 3.5 (1.0- 5.5) for the patients 
assigned female and 6.0 (3.0- 7.5) for the patients assigned male at 
birth (P = .002). This difference in the EMS between the two sexes 
was observed in the patients assigned before and after the year 
1990.
Four patients changed their gender in adulthood, two from male 
to female and two from female to male. These four patients visited 
our hospital at an adult age.
The patients were grouped on the basis of their gender and not 
on their sex assignment.
3.2 | Female gender group (n = 13)
Two patients came at prepubertal age (patients 1 and 2), four at 
pubertal (patients 3- 6) and seven after pubertal age (patients 
7- 13). Three patients had already had a gonadectomy and geni-
toplasty (patients 6, 7 and 9). Amongst the 10 patients without 
previous genital surgery, external genitalia ranged from normal 
female (patient 12), female with clitoromegaly (patients 1- 5, 8 
and 11) to micropenis (patient 11). Six patients had two perineal 
openings (patients 1, 3, 4, 5, 6 and 13), and five patients had a 
single perineal opening (patients 2, 8, 10, 11 and 12). All the 
patients had bilateral cryptorchidism. These patients had el-
evated serum gonadotropin levels with predominance of FSH 
levels (range from 38 to 77 IU/L) over LH levels (range from 5 to 
32 IU/L) Table 1.
All female patients had undergone feminizing genitoplasty and 
bilateral gonadectomy. Oestrogen replacement was started at a me-
dian age of 14 (10- 31 years) with normal breast development.
3.3 | Male gender group (n = 20)
Twelve patients were evaluated at prepubertal age (patients 14- 18, 
24- 30), three at pubertal age (patients 19, 20 and 31) and five after 
puberty (patients 21- 23, 32 and 33). At first evaluation, three pa-
tients had a previous genitoplasty (patients 20, 21 and 29), two had 
undergone bilateral gonadectomy (patients 20, 21) and one unilat-
eral gonadectomy (patient 29) Tables 2,3.
Regarding the 17 remaining patients, 12 had microphallus and 
proximal hypospadias (71%), 14 had bilateral cryptorchidism (82%), 
had unilateral cryptorchidism and one patient had both testes lying 
inside the scrotum.
The patients with low basal and/or hCG- stimulated testosterone 
levels had undergone bilateral gonadectomy. All of them received 
testosterone replacement at a median age of 15 (11.7- 48 years). 
Their median phallus size at first visit was −3.4 SD (−6.1 to −1.7 SD), 
and in adulthood, after testosterone replacement, the phallus size 
reached a median of 9 cm (range 6.7- 12 cm), corresponding to 
−2.7 SD (range −4.1 to −0.9 SD).
Patients with preserved testosterone secretion with one atro-
phic cryptorchid testis had had unilateral gonadectomy. The median 
phallus size of these patients at first visit was −3.3 SD (range −4.3 to 
−0.3 SD). In adulthood, phallus size reached a median of 8 cm (6.5- 
9.2 cm), corresponding to −3.3 SD (−4.3 to −2.6 SD).
There was no statistically significant difference in phallus size 
SDs between the patients with preserved testosterone secretion 
and those who received testosterone replacement and also at their 
first and last evaluation.
3.4 | Testosterone production in patients with 
46,XY PGD
At first evaluation, 28 patients who did not undergo bilateral go-
nadectomy in childhood were evaluated regarding testosterone 
production (Figure 1). Fourteen of them were at prepubertal age 
(patients 1, 2, 14- 18, and 24- 30). Eight of them had normal hCG- 
stimulated testosterone levels (patients 1, 2, and 25- 30), median of 
13.8 nmol/L (6.2- 22.1 nmol/L) and one patient at minipuberty had 
normal basal testosterone levels (patient 24). The other five individ-
uals (patients 14- 18) showed very low hCG- stimulated testosterone 
levels (undetectable to 2.9 nmol/L). All the male patients with im-
paired testosterone secretion and two female patients (patients 1 
and 2) had had bilateral gonadectomy.
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Among the 21 patients without bilateral gonadectomy, 12 
went through spontaneous puberty (patients 3, 4, 5, 13, 25- 29, 
and 31- 33), including four female patients (patients 3, 4, 5, and 13; 
Figure 1). These female patients and the two male patients who de-
veloped a gonadal tumour (patients 31 and 32) underwent bilateral 
gonadectomy. Patient 29 progressively lost testosterone secretion 
and started testosterone replacement at the age of 34 (Figure 1).
At last evaluation, five male patients maintained normal male 
adult testosterone levels (median 16.7 nmol/L). Four patients had 
high LH (median 11 IU/L) and FSH levels (median 24 IU/L), and one 
subject had normal gonadotropin levels (patient 25) at 17 years of 
age Table 4.
Altogether, twelve patients (57%) had gone through sponta-
neous puberty. At last evaluation, five of eight patients with male 
social sex who had gone through spontaneous puberty still had nor-
mal testosterone production.
3.5 | Psychosexual follow- up according to gender
Ten patients assigned female and 11 patients assigned male at birth 
were evaluated. Gender dysphoria and gender change were ob-
served in four patients, two from each gender group. None of the 
patients reported nonbinary or gender- fluid feelings.
Patients 8 and 11 were assigned male at birth. The former had 
atypical genitalia, and the latter had severe micropenis and bilateral 
cryptorchidism. They clearly displayed female behaviour, preferring 
female activities and clothes since childhood. They received proper 
medical and psychological assistance at the ages of 19 and 30, re-
spectively. At the time, their hormonal profile showed hypergonad-
otropic hypogonadism without pubertal signs. Their psychological 
analysis revealed female gender identity and gender dysphoria. They 
changed their gender to female, had feminizing genital surgery and 
were treated with conjugated oestrogens.
Patients 21 and 33 had atypical genitalia and were first assigned 
female at birth. They had manifested male behaviour since child-
hood, preferring boys’ hobbies and clothes.
Patient 21 had a feminizing genitoplasty and gonadectomy at 
1.6 years of age elsewhere and had no psychological evaluation and 
follow- up. At age 19, he changed his gender to male, and testoster-
one replacement was started. At 27 years of age, he came to our 
institution looking for neophallus surgery.
Patient 33 never had medical assistance. He had had male gen-
der identity since he was 9 years old. Virilisation due to spontaneous 
puberty was noticed when he was 15 years of age. At the time, he 
changed his gender to male. He was first seen at our service at age 
26, when masculinizing genitoplasty was performed.
At final evaluation, all the 21 patients had gender identity con-
cordant with their self- reported gender role in childhood and were 
satisfied with their gender. Four females (40%) and eight males (73%) 
had a steady partner. Penetrative sexual intercourse was reported 
by eight females (80%) and by nine males (81%), among whom six fe-
males (75%) and eight males (81%) reported satisfaction with sexual 
life and orgasm.
None of the patients from both genders have offspring or ad-
opted children.
3.6 | Testosterone production and gender
There was no relation between postnatal testosterone levels and 
gender considering the highest serum testosterone level at baseline 
condition or after the hCG stimulation test observed at the follow-
up (P = .9).
3.7 | Incidence of gonadal tumours
During follow- up, patients underwent bilateral gonadectomy 
due to female gender, for impaired testosterone secretion, for 
an atrophic cryptorchid testis, or because of a gonadal tumour. 
Thirteen patients had bilateral or unilateral gonadectomy at prepu-
bertal age at a median age of 4 years (1.2- 8.8), and no evidence of 
germ cell neoplasia was found. Fifteen patients had a gonadectomy 
at pubertal age or in adulthood at a median age of 21 (9.9- 47.9), and 
a testicular tumour was found in two subjects (patients 31 and 32).
Patient 31 had bilateral gonadoblastoma at ages 18 and 20 and 
an in situ germ cell neoplasia in the right testis, despite the scrotal 
position of both testes, due to a WT1 (Wilms’ tumour 1) mutation, as 
previously reported.6 Patient 32 had a mixed germ cell tumour (80% 
embryonal carcinoma, 15% yolk sac tumour, 5% choriocarcinoma) 
with a gonadoblastoma in the left abdominal gonad at 23 years of 
age associated with very high levels of hCG (536 IU/L; reference 
level <3 IU/L). He underwent bilateral gonadectomy and chemother-
apy with a good response.
3.8 | Molecular diagnosis
Pathogenic or likely pathogenic variants were found in nine sporadic 
cases and in two familial cases, eight identified by Sanger sequencing 
and three by targeted massively parallel sequencing (Table 5). All the 
identified variants are heterozygous and located in genes previously 
associated with gonadal dysgenesis phenotypes (NR5A1, SRY, WT1, 
MAP3K1 and FGFR2). Nine variants had already been described,4-7,25 
and two variants are novel (in MAP3K1 and FGFR2, the familial cases). 
None of the variants was found in population databases, including 
the Brazilian ABraOM.23 NR5A1 defects were the most common, 
being responsible for 18% of the cases, and in silico and in vivo stud-
ies corroborated the deleteriousness of NR5A1 variants, as previ-
ously reported by our group.4,7 None of these patients had adrenal 
failure. Segregation analysis by Sanger sequencing was possible in 
eight of ten families and confirmed segregation with the phenotype 
in five families and de novo status of the two WT1 variants.
4  | DISCUSSION
The DSD due to 46,XY PGD is a rare disorder. It represents 19.6% 
in our cohort of 250 patients with a 46,XY DSD. The current study 
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is the largest 46,XY PGD cohort showing clinical outcomes and mo-
lecular analysis.
Sex assignment is the most controversial issue of DSD manage-
ment. In our cohort, most patients were assigned before the 1990s, and 
male sex assignment was significantly more frequent in patients with 
a higher EMS, in a ratio of 1.5 males to 1.0 female. The International 
Disorder of Sex Development (I- DSD) Registry reported an increase in 
the male- to- female sex assignment ratio in 46,XY dysgenetic DSD ba-
bies with time, starting from a ratio of 0.4 before the 1990s to a ratio 
of 1.5 in children born after 1999, regardless of the EMS.26
Despite this increasing trend on male sex assignment, there are 
scarce data on pubertal development of those patients. In our cohort, 
spontaneous puberty was observed in 57% of the patients who did 
not undergo bilateral gonadectomy in childhood. In adulthood, all 
the male patients maintained testosterone secretion, except for the 
oldest, who showed a decrease in testosterone secretion at the age 
of 34. They all had high LH levels (>10 IU/L), with the exception of 
the youngest, indicating partial Leydig cell dysfunction. Regarding 
reproductive function, high FSH levels (>20 IU/L) were found in most 
patients manifesting compromised spermatogenesis although the 
sperm count was not performed.
In one retrospective study on pubertal development of 46,XY 
PGD patients, 9 of 10 patients had gone through spontaneous pu-
berty with high FSH levels and progressive elevation of LH.2 These 
F IGURE  1 Flow chart of patients’ 
follow- up regarding testosterone 
secretion and gonadal tumour incidence
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patients had a mild- gonadal- dysgenesis phenotype as 60% had a 
penile urethra opening and all of them were assigned male at birth.2
In humans, the process of gonadal determination is quite com-
plex1 and a molecular defect was identified in 20% and 40% of the 
46,XY gonadal dysgenesis patients who were studied by Sanger27 
and target massively parallel sequencing, respectively.28 NR5A1 
and MAP3K1 allelic variants were the most frequent molecular 
diagnosis.28
In our study, likely pathogenic or pathogenic allelic variants were 
identified in 33% of the patients, in one of the following genes: 
NR5A1, SRY, WT1, MAP3K1 and FGFR2. NR5A1 defects (n = 6) were 
the most frequent in the whole cohort and also among the 12 pa-
tients who developed spontaneous puberty (n = 4). Moreover, three 
of these patients were assigned female at birth owing to their se-
verely undervirilised genitalia. This finding is in agreement with 
other reports.29-35 In those cases, the severe undervirilisation of 
external genitalia could not predict virilisation in adulthood because 
testosterone secretion recovered during puberty for unknown 
reasons.29-36
SRY defects have been mostly associated with complete gonadal 
dysgenesis and rarely with partial gonadal dysgenesis.25,37-39 The 
SRY p.Arg30Ile pathogenic allelic variant was identified in one of 
our patients with spontaneous puberty. This same variant was also 
found in another Brazilian family, including affected members with 
various phenotypes, ranging from complete to partial gonadal dys-
genesis.25 In vitro studies proved the deleteriousness of the vari-
ant.25 None of the reported patients with PGD due to SRY variants 
had preserved testosterone secretion.25,37-39
Missense defects in Wilms’ tumour suppressor gene 1 (WT1) 
cause Frasier and Denys- Drash syndromes.40,41 One of our patients 
with normal size testes and spontaneous puberty harboured the 
most common allelic variant in intron 9 of WT1, which is associated 
with Frasier syndrome.6 This syndrome is generally characterised by 
bilateral gonadal dysgenesis, female external genitalia, renal failure 
in the second decade of life and high risk of testicular gonadoblas-
toma. Instead, our patient had a predominantly male phenotype, 
with normal penile length and perineal hypospadias resembling the 
Denys- Drash phenotype. Even though there are five other cases of 
Frasier syndrome with a male phenotype,42-44 including one with 
a normal male phenotype,45 there are no reports of patients with 
spontaneous puberty.
The novel heterozygous variants MAP3K1p.Leu639Pro and 
FGFR2 p.Ser453Leu were found simultaneously in two 46,XY sisters 
within our cohort, both inherited from their unaffected mother. Both 
had severe undervirilised genitalia at first evaluation, although nor-
mal male testosterone levels were reached after hCG stimulation in 
the 1.2- year- old child, and her 9.4- year- old sister had pubertal male 
testosterone levels.
MAP3K1 was first associated with 46,XY DSDs by Pearlman 
et al.46 Targeted massively parallel sequencing has revealed previ-
ously reported and novel MAP3K1 variants not only in patients with 
complete gonadal dysgenesis but also in patients with PGD. There 
is no information on hormone profile and pubertal development of 
those patients.28,47,48
FGFR2 variants most commonly cause craniosynostosis syn-
dromes without any gonadal phenotype. Although there is one 
report of a heterozygous FGFR2 p.Cys342Tyr variant that was 
associated with complete gonadal dysgenesis and no report 
of patients with PGD.49 The FGFR2 p.Ser453Leu allelic variant 
found in one of our families is located in the hotspot region for 
pathogenic variants responsible for craniosynostosis pheno-
types; however, our patients and their mother did not have any 
skull problems.
The mechanism by which the gonadal FGF signal is transduced 
intracellularly remains unclear, but FGFR2 and MAP3K1 are members 
of the RAS/RAF/MEK/ERK signalling pathway, and these patients 
may have a digenic inheritance cause of gonadal dysgenesis.
The prevalence of germ cell tumours in PGD is variable. 
Reported rates range between 16% and 30%3 and for Denys- Drash 
and Frasier syndromes is as high as 40%- 60%.50 In our cohort, two 
patients (7%) had a germ cell tumour: one had an invasive semi-
noma, and the other had bilateral gonadoblastoma associated with 
in situ germ cell neoplasia. Both patients had additional factors for 
germ cell tumour development: one had an abdominal gonad, and 
the other had both testicles lying within the scrotum but carried a 
WT1 mutation.
TABLE  4 Phenotypes of 46,XY PGD male gender patients who had preserved testosterone secretion at final evaluation
Patient 25 26 27 28 33
Age (y) 17 17 17.6 21 28
Penile length (cm) 8.0 × 3.0 8.0 × 3.0 7.5 × 2.5 9.2 × 2.5 6.5 × 2.5
Z phallus (SD) −3.3 −3.3 −3.6 −2.6 −4.3
Testis final size (cm) 4.5 × 2.5 6.7 × 2.1 4.0 × 2.5 4.3 × 2.0 6.5 × 2.5
Basal Ta (nmol/L) 441 561 625 482 396
LH (IU/L) 5.6 14 11 11 10.8
FSH (IU/L) 3.7 26 25 24 20.7
PGD, Partial gonadal dysgenesis.
aImmunofluorometric assay (IFMA), normal male value: prepubertal age <0.65 nmol/L; adults 9.4- 33.5 nmol/L.
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Pre- and postnatal androgen exposure seems to contribute 
to male gender identity in patients with the 46,XY DSD due to 
5alpha- reductase type 2 and 17beta- hydroxysteroid dehydro-
genase type 3 deficiencies. In those patients, despite the severe 
undervirilisation and female rearing, a high rate of gender change 
to male is observed, ranging from 50% to 63% and from 39% to 
64%, respectively.51 In 46,XY PGD, testosterone production is 
quite variable during foetal and adult life. In our cohort, postna-
tal testosterone levels were not related to the gender. In addi-
tion, among the 5 patients assigned female at birth who virilised 
at puberty, 3 harboured NR5A1 variants, and gender change to 
male was observed in one patient, who reported gender dysphoria 
since childhood.
Gender dysphoria had rarely been observed in patients 
with PGD. To our knowledge, only one case of female- to- male 
gender change has been reported.34 This patient harboured a 
NR5A1 variant, was assigned female at birth, presented with vir-
ilisation at puberty and changed his gender at 18 years of age.34 
Nonetheless, no gender change was observed among another 
six PGD patients with NR5A1 defects already described, who 
had gone through spontaneous virilisation.29-31,33,35,36 Together 
with the already published cases of NR5A1 defects, among the 
10 patients assigned female at birth with virilisation at puberty, 
two patients changed their gender to male. This data does not 
suggests that testosterone production at puberty is a determi-
nant of gender change, but it should play a role in 46,XY PGD 
patients’ gender, although the small sample size does not allow 
us to make any conclusion.
The psychosexual evaluation in adulthood revealed that the pa-
tients were satisfied with their final social sex, and ~80% of the pa-
tients reported satisfaction with their sexual life.
5  | CONCLUSION
The present study represents the largest 46,XY PGD cohort 
showing clinical outcomes and molecular analysis. Spontaneous 
puberty was observed in 57% of the patients with 46,XY PGD, 
being NR5A1 defects the most prevalent among all patients and 
among those with spontaneous puberty. A germ cell tumour was 
detected only after puberty in 7% of the patients. Gender change 
due to gender dysphoria was reported by 12% of the patients. All 
the patients reported satisfaction with their gender and most of 
them with their sexual life.
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APPENDIX 1
Questionnaire applied to 46,XY disorder of sex development (DSD) patients due to partial gonadal dysgenesis regarding gender 
identification and sexual life quality
Social sex and gender identity
• At birth, your assigned social sex was: 1 - female 2 - male 3 - undefined
• Have you ever wished to change your gender? 1 - yes 2 - no
• Have you changed your gender?: 1 - yes 2 - no
• How old were you when you started thinking about to change your gender?
• How old were you when you changed your gender?
• Define your gender identification: 1 - female 2 - male 3 - both 4 - none
Self- reported gender role at childhood
• At childhood, you used to behave like you were: 1 - a girl 2 - a boy 3 - both
• At childhood, how you used to feel about your gender? 
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• Which were your preferable toys at childhood
Classification of the preferable toys at childhood according gender:
Typically female toys Typically boys toys Neutral boys
Dolls, make- ups, drawing, reading,  
costumes, board games
Cars and trucks, building games  
(like Lego)
Plays with ball, running, 
group activities
Sexual life aspects
• Do you have regular sexual intercourses? 1 - yes 2 - no
• Do you have a steady partner? 1 - yes 2 - no
• Do you have penetrative sexual intercourses? 1 - yes 2 - no
• Are you satisfied with your sexual life? 1 - yes 2 - no
• Do you have orgasm during intercourse? 1 - yes 2 - no
APPENDIX 2
List of genes related to disorders of sex development (DSDs) included in the panel for targeted massively parallel sequencing
Gene
Associated phenotype already related to human DSDs reported in OMIM (OMIM number) or in the literature 
(L)1 (n = 43) Inheritance
Gonadal development genes
 BMP15 Ovarian dysgenesis 2 (300510); Premature ovarian failure 4 (300510) XL
 CBX2 46,XY sex reversal 5 (613080); 46,XY complete gonadal dysgenesis (L) AR
 DHH 46XY partial gonadal dysgenesis, with minifascicular neuropathy (607080); 46XY sex reversal 7 (233420) AR
 DMRT1 Dysgenetic testis or ovotestis (L) AD
 DMRT2 Haploinsufficiency 9p sex- determining gene leads to gonadal dysgenesis (L) NA
 FGFR2 46,XY sex reversal with craniosynostosis (L) AD, AR
 FOXL2 Premature ovarian failure 3 (608996); blepharophimosis, epicanthus inversus, and ptosis, type 1 and 2 (110100) AD
 GATA4 Testicular anomalies with or without congenital heart disease (615542) AD
 MAP3K1 46XY sex reversal 6 (613762) AD
 NR0B1 46XY sex reversal 2, dosage- sensitive (300018) XL
 NR5A1 46, XX sex reversal 4 (617480); 46XY sex reversal 3 (612965); premature ovarian failure 7 (612964) AD
 RSPO1 Palmoplantar hyperkeratosis and true hermaphroditism (610644); palmoplantar hyperkeratosis with squamous 
cell carcinoma of skin and sex reversal (610644)
AR
 SOX 9 Campomelic dysplasia with autosomal sex reversal (114290) AD
 SOX3 46,XX testicular or ovotesticular DSD (L); 46,XX Sex Reversal 3 (300833) XL
 SRY 46XX sex reversal 1 (400045); 46XY sex reversal 1 (400044) Y- linked
 STAG3 Premature ovarian failure 8 (615723) AR
 WNT4 Mullerian aplasia and hyperandrogenism (158330) AD
 WT1 Denys- Drash syndrome (194080); Frasier syndrome(136680) AD
 WWOX 46,XY gonadal dysgenesis (L) Y- linked
 ZFPM2 46XY sex reversal 9 (616067) AD
Sexual differentiation genes
 AKR1C2 46XY sex reversal 8 (614279) AR
 AKR1C4 46XY sex reversal 8, modifier (614279) AR
 AMH Persistent Mullerian duct syndrome, type I (261550) AR
 AMHR2 Persistent Mullerian duct syndrome, type I (261550) AR
 AR Androgen insensitivity (300068); Hypospadias 1, X- linked (300633) X- L
 CYP17A1 17,20- lyase deficiency, isolated (202110) AR
 CYP19A1 Aromatase deficiency (613546); aromatase excess syndrome (139300) AD
 CYP21A2 Adrenal hyperplasia, congenital, due to 21- hydroxylase deficiency (201910) AR
 DHCR7 Smith- Lemli- Opitz syndrome (270400) AR
 FSHR Ovarian dysgenesis 1 (233300) AR
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Gene
Associated phenotype already related to human DSDs reported in OMIM (OMIM number) or in the literature 
(L)1 (n = 43) Inheritance
 HSD11B1 Cortisone reductase deficiency 2 (614662) AD
 HSD17B3 Pseudohermaphroditism, male, with gynecomastia (264300) AD
 HSD3B2 3- beta- hydroxysteroid dehydrogenase, type II, deficiency (201810) AD
 LHCGR Leydig cell hypoplasia with pseudohermaphroditism (238320); Leydig cell hypoplasia with hypergonadotropic 
hypogonadism (238320)
AR
 POR Antley- Bixler syndrome with genital anomalies and disordered steroidogenesis (201750); Disordered steroido-
genesis due to cytochrome P450 oxidoreductase (613571)
AR
 SRD5A2 Pseudovaginalperineoscrotal hypospadias (264600) AR
 STAR Lipoid adrenal hyperplasia (201710) AR
Other (syndromic DSD, isolated hypospadias)
 ARX Hydranencephaly with abnormal genitalia (300215) X- L
 ATRX ATR- X syndrome with gonadal abnormalities (301040) X- LD/X- LR
 CDH7 CHARGE syndrome (214800); hypogonadotropic hypogonadism with or without anosmia (612370) AD
 HNF1B Mayer- Rokitansky- Kuster- Hauser syndrome (L) AD
 LHX1 Mayer- Rokitansky- Kuster- Hauser syndrome (L) AD
 MAMLD1 Hypospadias, X- linked (300758) XL
Gene Candidate genes associated with human DSDs selected from the literature (L) and in OMIM (O) (n = 20) Inheritance
AKR1C3 Testosterone production in the adrenal reticularis18 NA
AXIN1 Wnt- beta- catenin signaling (O) NA
CITED2 An upstream regulator of NR5A1 (L)1 NA
ESR1 Sex reversal in ESRA/ESRB knockout males (O) NA
ESR2 46,XY DSD candidate gene (L)11 AR;AD
FGF9 XY mice KO results in male- to- female sex reversal (L)12 NA
GDF9 Ovarian development (L)12 NA
GSK3β Wnt- beta- catenin signalling (O) NA
LHX9 Gonadal formation in mouse model (L)1 NA
NANOS2 Expressed in adult and foetal testis (O) NA
NANOS3 Nanos3- null mice present reduced spermatogenesis (O) NA
PAPPA Expressed in ovarian follicles and in the seminal vesicles and fluid (O) NA
PAX2 WT1 pathway (L)13 NA
PBX1 Müllerian development in the mouse (L)13 NA
PTDGS Required for testis formation (L)1 NA
RAC1 Formation of primordial follicles in mouse (L)14 NA
RSPO2 Essential for primary follicle development (L)15 NA
STRA8 Premeiotic DNA replication (L)16 NA
TCF21 SRY pathway (L)17 NA
TES Testis- specific enhancer of Sox9 (L)1 NA
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